OmniAb, Inc. (NASDAQ:OABI) Shares Purchased by Janus Henderson Group PLC

Janus Henderson Group PLC raised its stake in OmniAb, Inc. (NASDAQ:OABI) by 0.0% in the third quarter, HoldingsChannel.com reports. The fund owned 7,871,328 shares of the company’s stock after purchasing an additional 3,104 shares during the quarter. Janus Henderson Group PLC owned about 0.07% of OmniAb worth $33,296,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in OABI. Palumbo Wealth Management LLC increased its position in OmniAb by 12.5% during the 3rd quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock worth $104,000 after purchasing an additional 2,744 shares in the last quarter. Sei Investments Co. grew its holdings in shares of OmniAb by 11.0% during the second quarter. Sei Investments Co. now owns 29,024 shares of the company’s stock worth $109,000 after buying an additional 2,888 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of OmniAb by 13.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 26,843 shares of the company’s stock worth $146,000 after buying an additional 3,108 shares in the last quarter. Simplicity Wealth LLC raised its position in shares of OmniAb by 23.3% in the second quarter. Simplicity Wealth LLC now owns 42,160 shares of the company’s stock valued at $158,000 after buying an additional 7,976 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of OmniAb by 64.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock valued at $96,000 after buying an additional 8,909 shares during the period. 72.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Benchmark reaffirmed a “buy” rating and issued a $8.00 target price on shares of OmniAb in a research note on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of OmniAb in a research note on Thursday, November 14th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $7.00 target price on shares of OmniAb in a research report on Friday, August 16th.

OmniAb Stock Up 3.9 %

NASDAQ:OABI opened at $4.02 on Friday. OmniAb, Inc. has a fifty-two week low of $3.56 and a fifty-two week high of $6.72. The firm’s 50 day moving average is $4.04 and its two-hundred day moving average is $4.21. The company has a market cap of $567.69 million, a P/E ratio of -6.48 and a beta of -0.14.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.